|
Goodwill and intangible assets (Details) (USD $)
|
1 Months Ended | 3 Months Ended | 12 Months Ended | 12 Months Ended | 1 Months Ended | 3 Months Ended | 12 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
May 31, 2014
|
May 31, 2013
|
Jul. 31, 2012
|
Jul. 31, 2014
|
Jul. 31, 2013
|
Jul. 31, 2012
|
Jul. 31, 2014
Clinical Labs [Member]
|
Jul. 31, 2013
Clinical Labs [Member]
|
Jul. 31, 2012
Enzo Life Sciences [Member]
|
May 31, 2012
Trademarks [Member]
|
Jul. 31, 2012
Trademarks [Member]
|
Jul. 31, 2014
Trademarks [Member]
|
Jul. 31, 2014
Intangible Assets, Amortization Period [Member]
|
|
| Goodwill and intangible assets (Details) [Line Items] | |||||||||||||
| Goodwill | $ 7,452,000 | $ 7,452,000 | $ 7,452,000 | $ 7,452,000 | |||||||||
| Percentage Of Stock Price Result Of Decline Market Capitalization | 44.00% | ||||||||||||
| Asset Impairment Charges | 24,540,000 | 18,800,000 | 5,700,000 | ||||||||||
| Asset Impairment Charges Net of Taxes | 22,400,000 | 18,000,000 | 4,400,000 | ||||||||||
| Finite-Lived Intangible Asset, Useful Life | 10 years | 5 years | 5 years | 5 years | |||||||||
| Amortization of Intangible Assets | 1,840,000 | 1,990,000 | 1,660,000 | 600,000 | |||||||||
| Finite-Lived Intangible Assets, Period Increase (Decrease) | 5,700,000 | ||||||||||||
| Goodwill, Impairment Loss | $ 0 | $ 0 | |||||||||||
| X | ||||||||||
|
- Definition
The value of asset impairment of intangible asset. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Percentage of stock price result of decline market capitalization. No definition available.
|
| X | ||||||||||
|
- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. No definition available.
|
| X | ||||||||||
|
- Definition
Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. No definition available.
|
| X | ||||||||||
|
- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|